INSILICO (03696) has reached a high-value AI-driven research and development collaboration in the field of neuroimmunology diseases with SK Biopharmaceuticals worth up to 2.5 billion USD.

INSILICO (03696) announced that it has entered into a research and development collaboration with SK Biopharmaceuticals (SK BioPharm) to explore innovative candidate drugs for central nervous system immune diseases driven by AI. In this collaboration, INSILICO will utilize its proprietary Pharma.AI platform, which covers target validation, generative chemistry, and molecular optimization, along with its expertise in preclinical drug discovery, to discover, design, and optimize novel candidate drugs for neuroimmune disorders. SK Biopharmaceuticals will leverage its deep research and clinical capabilities in the field of neuroimmune diseases to lead the later-stage development and commercialization of all collaboration programs. Under the terms of the agreement, INSILICO will be eligible to receive up to $18 million in upfront payment and near-term milestone payments. The potential total value of the collaboration exceeds $2.5 billion, including development, regulatory, and commercialization milestone payments, as well as single-digit percentage royalties on net sales post-commercialization.